Latest Regulatory Filings News

Native Mineral Resources has successfully poured 1,543 ounces of gold doré at its Blackjack Processing Plant, while progressing key operational and regulatory initiatives to optimise mining and processing activities.

Bubalus Resources has responded to ASX concerns over a delayed director interest notice, attributing the lapse to an administrative oversight and reaffirming its commitment to compliance.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Bridge SaaS Limited has issued a correction to its Appendix 4C quarterly cash flow report, clarifying previously omitted financing facilities without affecting its cash position or operating results.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Native Mineral Resources’ board members have converted $1.62 million in options into 63 million new shares, reinforcing their commitment to the company’s growth strategy and key projects in northern Queensland.

WRKR Ltd has completed its strategic acquisition of PaidRight Holdings, issuing over 90 million shares to expand its compliance platform into payroll compliance. This move marks a significant step beyond superannuation, aiming to create a comprehensive compliance solution.

Livium Ltd announces a further A$335,000 distribution from its 50% stake in the LieNA joint venture, following receipt of a substantial R&D tax incentive rebate for FY25. The joint venture remains well-funded through FY27, supporting ongoing lithium extraction technology development.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.